Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase1 study to assess the safety, PK, PD and efficacy of HM97662, EZH1/2 dual
inhibitor, in solid tumors. The study will be conducted in Dose-Escalation and Dose-Expansion
parts. Dose-Escalation Part is planned with a 3+3 Dose-Escalation design and is to establish
the MTD or RD for Dose-Expansion part of HM97662 as a single agent in subjects with advanced
or metastatic solid tumors. Dose-Expansion Part is designed to assess the potential efficacy
of HM97662 monotherapy when administered at the RD to subjects in indication-specific
expansion cohorts.